New drug elranatamab tested in Real-World chinese myeloma patients

NCT ID NCT07320326

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatamab works in real-world settings and to improve treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elranatamab
What this could lead to: If successful, this study could confirm that elranatamab works well in Chinese patients with hard-to-treat multiple myeloma, helping doctors use it more effectively.
What could go wrong: This is an observational registry, not a controlled trial, so results may be less definitive. It is also early-stage in China, and effectiveness may vary across patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TCE-RRMM

Contacts and locations

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.